Repurposing Ivermectin and Mebendazole for Cancer: What the New Real-World Data Tells Us, and What It Cannot
I believe the preclinical case for ivermectin and mebendazole as anticancer agents is real, multi-mechanistic, and worth taking seriously. I believe the Hulscher cohort adds a meaningful safety and tolerability signal in real-world cancer patients, and that the responses some participants reported are encouraging enough to justify urgent randomized trials.


















